Article: Genaera Corporation Presents Clinical Results for EVIZON(TM) for Treatment of Age-Related Macular Degeneration at the Annual ASRS Meeting.

PLYMOUTH MEETING, Pa., July 18 /PRNewswire-FirstCall/ -- Genaera Corporation today announced the presentation of clinical trial results from two U.S. Phase II clinical trials with EVIZON(TM) (squalamine lactate) for the treatment of choroidal neovascularization associated with age-related macular degeneration (AMD), also known as "wet" AMD. EVIZON is the leading systemically delivered anti-angiogenic drug being developed to treat AMD. The presentations were held at the 23rd Annual Meeting of the American Society of Retina Specialists (ASRS) in Montreal, Quebec, Canada.

Brian P. Connolly, MD, Retina Research Services, Wills Eye Hospital, Philadelphia, ...

Related newspaper, magazine, and journal articles:

 
 
Newsweek Harper's Magazine The Washington Post Chicago Tribune Crain's Chicago Business PRNewswire Pediatric News The Nation Advertising Age The Economist (US) A FREE trial gives you access to over 80 million articles! Access over 6,500 publications with a FREE trial!